Related Experiment Video
Updated: Jun 21, 2025
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
Published on: September 16, 2020
Effect of Oridonin on Experimental Animal Model of Bronchopulmonary Dysplasia
Shanshan Zhang1, Junfu Wang2, Zhihong Xin3
1Department of Emergency, The Second Hospital of Shandong University, Jinan, China.
Insights
Oridonin, a traditional Chinese medicine, effectively reduces inflammation and lung injury in a neonatal rat model of bronchopulmonary dysplasia (BPD). This study suggests Oridonin as a potential therapeutic for BPD.
Area of Science:
- Neonatal medicine
- Pharmacology
- Inflammation research
Background:
- Bronchopulmonary dysplasia (BPD) is a prevalent respiratory disease in premature infants with no effective treatments.
- Inflammation is a critical factor in the pathogenesis of BPD.
- Oridonin (Ori), a compound from traditional Chinese medicine, possesses known anti-inflammatory properties.
Purpose of the Study:
- To investigate the therapeutic potential of Oridonin (Ori) in an experimental animal model of bronchopulmonary dysplasia (BPD).
- To evaluate the anti-inflammatory effects of Oridonin in the context of BPD.
Main Methods:
- Development of a BPD model in neonatal rats using hyperoxia exposure.
- Administration of Oridonin (Ori) to neonatal rats with induced BPD.
- Assessment of lung injury, neutrophil infiltration, myeloperoxidase activity, and inflammatory cytokine levels.
Main Results:
- Oridonin significantly reduced hyperoxia-induced alveolar injury in neonatal rats.
- Ori administration inhibited neutrophil recruitment and decreased myeloperoxidase concentrations.
- Oridonin treatment suppressed the release of key inflammatory factors in the BPD model.
Conclusions:
- Oridonin demonstrates significant therapeutic effects in a neonatal rat model of bronchopulmonary dysplasia (BPD).
- The anti-inflammatory activity of Oridonin is key to its beneficial effects on BPD.
- Oridonin shows promise as a potential treatment for BPD by mitigating inflammatory responses.
Abstract:
Bronchopulmonary dysplasia (BPD) is a serious disease that occurs in premature and low-birth-weight infants. In recent years, the incidence of BPD has not decreased, and there is no effective treatment for it. Oridonin (Ori) is a traditional Chinese medicine with a wide range of biological activities, especially pharmacological and anti-inflammatory. It is well known that inflammation plays a key role in BPD. However, the therapeutic effect of Ori on BPD has not been studied. Therefore, in the present study, we will observe the anti-inflammatory activity of Ori in an experimental animal model of BPD. Here, we showed that Ori could significantly decrease hyperoxia-induced alveolar injury, inhibit neutrophil recruitment, myeloperoxidase concentrations, and release inflammatory factors in BPD neonatal rats. Taken together, the experimental results suggested that Ori can significantly improve BPD in neonatal rats by inhibiting inflammatory response.
